Analysts Set $23.00 Target Price for Safeguard Scientifics Inc. (SFE)
Shares of Safeguard Scientifics Inc. (NYSE:SFE) have been assigned a consensus broker rating score of 1.75 (Buy) from the four analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation, one has issued a buy recommendation and two have assigned a strong buy recommendation to the company.
Brokers have set a 1 year consensus price target of $23.00 for the company, according to Zacks. Zacks has also assigned Safeguard Scientifics an industry rank of 206 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research raised shares of Safeguard Scientifics from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Wednesday, October 12th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/18/analysts-set-23-00-target-price-for-safeguard-scientifics-inc-sfe.html
Shares of Safeguard Scientifics (NYSE:SFE) traded up 2.16% during midday trading on Tuesday, hitting $13.22. 3,073 shares of the stock were exchanged. Safeguard Scientifics has a 1-year low of $11.40 and a 1-year high of $18.07. The firm’s market capitalization is $267.36 million. The stock’s 50-day moving average price is $13.31 and its 200-day moving average price is $13.32.
Safeguard Scientifics (NYSE:SFE) last announced its quarterly earnings data on Thursday, July 28th. The company reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.45. During the same quarter in the prior year, the company posted ($0.91) EPS. On average, analysts forecast that Safeguard Scientifics will post $0.24 EPS for the current year.
In other news, CEO Stephen T. Zarrilli bought 3,900 shares of Safeguard Scientifics stock in a transaction on Wednesday, September 14th. The stock was purchased at an average cost of $12.75 per share, with a total value of $49,725.00. Following the purchase, the chief executive officer now directly owns 103,606 shares of the company’s stock, valued at approximately $1,320,976.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 2.67% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of SFE. Bank of Montreal Can purchased a new position in Safeguard Scientifics during the second quarter worth about $5,664,000. Keane Capital Partners LLC purchased a new position in Safeguard Scientifics during the first quarter worth about $1,132,000. United Services Automobile Association raised its position in Safeguard Scientifics by 58.1% in the second quarter. United Services Automobile Association now owns 227,688 shares of the company’s stock worth $2,844,000 after buying an additional 83,700 shares during the last quarter. Renaissance Technologies LLC raised its position in Safeguard Scientifics by 216.0% in the first quarter. Renaissance Technologies LLC now owns 94,800 shares of the company’s stock worth $1,256,000 after buying an additional 64,800 shares during the last quarter. Finally, Yakira Capital Management Inc. raised its position in Safeguard Scientifics by 14.3% in the first quarter. Yakira Capital Management Inc. now owns 487,645 shares of the company’s stock worth $6,461,000 after buying an additional 60,823 shares during the last quarter. 78.63% of the stock is owned by hedge funds and other institutional investors.
About Safeguard Scientifics
Safeguard Scientifics, Inc provides capital, as well as strategic, operational and management resources to growth-stage businesses. The Company participates in early- and growth-stage financings. The Company operates through two segments: Healthcare and Technology. The Healthcare segment’s companies focuses principally on medical technology (MedTech), including diagnostics and devices, and healthcare technology (HealthTech).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Safeguard Scientifics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Safeguard Scientifics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.